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Clinical Trial Registration — Looking Back and Moving Ahead
In 2005, the International Committee of Medical 
Journal Editors (ICMJE) initiated a policy requir­
ing investigators to deposit information about 
trial design into an accepted clinical trials regis­
try before the onset of patient enrollment.1 This 
policy aimed to ensure that information about 
the existence and design of clinically directive 
trials was publicly available, an ideal that leaders 
in evidence­based medicine have advocated for 
decades.2 The policy precipitated much angst 
among research investigators and sponsors, who 
feared that registration would be burdensome 
and would stifle competition. Yet, the response to 
this policy has been overwhelming. The ICMJE 
promised to reevaluate the policy in 2 years after 
implementation. Here, we summarize that re­
evaluation, specifically commenting on registries 
that meet the policy requirements, the types of 
studies that require registration, and the regis­
tration of trial results. As is always the case, the 
ICMJE establishes policy only for the 12 member 
journals (a detailed description of the ICMJE and 
its purpose is available at www.icmje.org), but 
many other journals have adopted our initial trial 
registration recommendations, and we hope that 
they will also adopt the modifications discussed 
in this update.
The research community has embraced trial 
registration. Before the ICMJE policy, ClinicalTrials.
gov, the largest trial registry at the time, contained 
13,153 trials; this number climbed to 22,714 
1 month after the policy went into effect.3 In April 
2007, the registry contained over 40,000 trials, 
with more than 200 new trial registrations occur­
ring weekly (Zarin D: personal communication). 
The four other registries that meet the ICMJE cri­
teria have also grown as scores of journals have 
adopted the ICMJE clinical trials registration pol­
icy. In response to burgeoning registration, many 
investigators, sponsors, and government agencies 
have asked the ICMJE to recognize their local 
registries as databases that meet the policy. For­
tunately, the World Health Organization’s (WHO) 
International Clinical Trial Registry Platform 
(ICTRP), which was nascent when the ICMJE be­
gan to require trial registration, has matured rap­
idly and provides options for those that desire a 
wider array of registries. The ICTRP has taken the 
first steps toward developing a network of pri­
mary and partner registers that meet WHO­spec­
ified criteria.4 Primary registers are WHO­select­
ed registers managed by not­for­profit entities 
that will accept registrations for any intervention­
al trials, delete duplicate entries from their own 
register, and provide data directly to the WHO. 
Partner registers, which will be more numerous, 
will include registers that submit data to primary 
registers but limit their own register to trials in 
a restricted area (such as a specific disease, com­
pany, academic institution, or geographic region).
The ICMJE strongly supports the WHO’s ef­
forts, through the ICTRP, to develop a coordinated 
process for identifying, gathering, deduplicating, 
and searching trials from registries around the 
world, thus eventually providing a one­stop search 
portal for those seeking information about clin­
ical trials. In addition to the five existing regis­
tries, the ICMJE will now also accept registration 
in any of the primary registers that participate in 
the WHO ICTRP. Because it is critical that trial 
registries are independent of for­profit interests, 
the ICMJE policy requires registration in a WHO 
primary register rather than solely in a partner 
register, since for­profit entities manage some 
partner registers. As previously, trial registration 
with missing or uninformative fields for the min­
imum data elements is inadequate.1
Initially, the ICMJE required registration of 
all clinically directive trials, which it defined as 
“any research project that prospectively assigns 
human subjects to intervention or comparison 
groups to study the cause­and­effect relationship 
between a medical intervention and a health 
outcome.”1 In May 2005, the ICMJE clarified this 
definition to exclude preliminary trials designed 
to study pharmacokinetics or major unknown 
toxicity (phase 1 trials).5 However, the ICMJE 
recognizes the potential benefit of having infor­
mation about preliminary trials in the public 
domain, because these studies can guide future 
research or signal safety concerns. Consequent­
ly, the ICMJE is expanding the definition of the 
types of trials that must be registered to include 
these preliminary trials and adopts the WHO’s 
definition of clinical trial: “any research study 
that prospectively assigns human participants or 
groups of humans to one or more health­related 
interventions to evaluate the effects on health 
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outcomes.” 4 Health­related interventions include 
any intervention used to modify a biomedical or 
health­related outcome (for example, drugs, sur­
gical procedures, devices, behavioral treatments, 
dietary interventions, and process­of­care chang­
es). Health outcomes include any biomedical or 
health­related measures obtained in patients or 
participants, including pharmacokinetic measures 
and adverse events. As previously, purely obser­
vational studies (those in which the assignment 
of the medical intervention is not at the discre­
tion of the investigator) will not require registra­
tion. The ICMJE member journals will start to 
implement the expanded definition of clinically 
directive trials for all trials that begin enrollment 
on or after July 1, 2008. Those who are uncertain 
whether their trial meets the expanded ICMJE def­
inition should err on the side of registration if 
they wish to seek publication in an ICMJE journal.
Over the time during which registration of trial 
methods has become common practice, several 
forces have begun advocating for registration of 
trial results. We recognize that the climate for 
results registration will probably change dramati­
cally and unpredictably over coming years. For 
the present, the ICMJE will not consider results 
posted in the same primary clinical trials regis­
ter in which the initial registration resides as 
previous publication if the results are presented 
in the form of a brief (<500 words) structured 
abstract or table. The ICMJE favors a standard 
abstract format for results reporting, and the 
CONSORT (Consolidated Standards for the Re­
porting of Trials) group’s forthcoming guidelines 
for abstracts related to trials may be one such op­
tion. The ICMJE believes that parties interested 
in results registration should consider requiring 
the deposition of such an abstract in the registry 
24 months after closure of data collection if re­
sults are not published in a peer­reviewed venue 
by that time. The registered abstract should ei­
ther cite any related full, peer­reviewed publica­
tions or include a statement that indicates that 
the report has not yet been published in a peer­
reviewed journal. Researchers should be aware 
that editors may consider more detailed deposi­
tion of trial results in publicly available regis­
tries to be prior publication. When submitting a 
paper, authors should fully disclose to editors 
all posting in registries of results of the same or 
closely related work.
Three years ago, trials registration was the 
exception; now it is the rule. Registration facili­
tates the dissemination of information among 
clinicians, researchers, and patients, and it helps 
to assure trial participants that the information 
that accrues as a result of their altruism will be­
come part of the public record. The WHO’s global 
efforts toward comprehensive trials registration 
and the ICMJE’s requirements for registration aim 
to increase public trust in medical science.
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Key Summary Points
In addition to accepting registration in any of the five 
 existing registries, the ICMJE will accept registration 
of clinical trials in any of the primary registers that 
participate in the WHO ICTRP. Registration in a 
partner register only is insufficient.
The ICMJE will begin to implement the WHO definition 
of clinical trials for all trials that begin enrollment  
on or after July 1, 2008. This definition states that a 
clinical trial is “any research study that prospectively 
 assigns human participants or groups of humans to 
one or more health-related interventions to evaluate 
the effects on health outcomes.”
The ICMJE will not consider results posted in the same 
clinical trials registry in which the primary registration 
resides to be previous publication if the results are 
presented in the form of a brief (<500 words) struc-
tured  abstract or table.
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